• 1

    Jemal A, Siegel R, Ward E et al. . Cancer statistics, 2008. CA Cancer J Clin 2008;76:7196.

  • 2

    Wasco MJ, Daignault S, Zhang Y et al. . Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. Urology 2007;70:6974.

    • Search Google Scholar
    • Export Citation
  • 3

    Herr HW, Shipley WU, Bajorin DF. Cancer of the bladder. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001.

    • Search Google Scholar
    • Export Citation
  • 4

    Hall RR, Parmar MK, Richards AB, Smith PH. Changes in cystoscopic follow up in patients with bladder cancer and adjuvant intravesical chemotherapy. BMJ 1994;308:257260.

    • Search Google Scholar
    • Export Citation
  • 5

    Greene FL, Page DL, Fleming ID et al. ., eds. AJCC Cancer Staging Manual, 6th ed. New York: AJCC Springer-Verlag; 2002.

  • 6

    Montironi R, Lopez-Beltran A. The 2004 WHO classification of bladder tumors: a summary and commentary. Int J Surg Pathol 2005;13:143153.

  • 7

    Smith JA Jr, Labasky RF, Cockett AT et al. . Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1, and TIS). J Urol 1999;162:16971701.

    • Search Google Scholar
    • Export Citation
  • 8

    Dutta SC, Smith JA Jr, Shappell SB et al. . Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 2001;166:490493.

    • Search Google Scholar
    • Export Citation
  • 9

    Schwaibold HE, Sivalingam S, May F, Hartung R. The value of a second transurethral resection for T1 bladder cancer. BJU Int 2006;97:11991201.

  • 10

    Shelley MD, Kynaston H, Court J et al. . A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection versus transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001;88:209216.

    • Search Google Scholar
    • Export Citation
  • 11

    Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006;67:12161223.

    • Search Google Scholar
    • Export Citation
  • 12

    Shelley MD, Wilt TJ, Court J et al. . Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004;93:485490.

    • Search Google Scholar
    • Export Citation
  • 13

    Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:9095.

    • Search Google Scholar
    • Export Citation
  • 14

    Lokeshwar VB, Habuchi T, Grossman HB et al. . Bladder tumor markers beyond cytology: international consensus panel on bladder tumor markers. Urology 2005;66(Suppl 6A):3563.

    • Search Google Scholar
    • Export Citation
  • 15

    Herr H, Sogni PC. Does early cystectomy improve survival of patients with high-risk superficial bladder tumors? J Urol 2001;166:12961299.

  • 16

    Joudi FN, Smith BJ, O’Donnell MA. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 2006;24:344348.

    • Search Google Scholar
    • Export Citation
  • 17

    Bohle A, Bock PR. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004;63:682686; discussion 686–687.

    • Search Google Scholar
    • Export Citation
  • 18

    Shelley MD, Wilt TJ, Court J et al. . Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004;93:485490.

    • Search Google Scholar
    • Export Citation
  • 19

    Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta analysis of the published results of randomized clinical trials. J Urol 2002;168:19641970.

    • Search Google Scholar
    • Export Citation
  • 20

    Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus Calmette-Guérin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005;174:8691; discussion 91–82.

    • Search Google Scholar
    • Export Citation
  • 21

    Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006;67:12161223.

    • Search Google Scholar
    • Export Citation
  • 22

    Nieder AM, Brausi M, Lamm D et al. . Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 2006;66:108125.

  • 23

    Witjee JA. Management of BCG failures in superficial bladder cancer: a review. Eur Urol 2006;49:790797.

  • 24

    Kim B, Semelka RC, Ascher SM et al. . Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enchanced imaging, and late gadolinium-enhancing imaging. Radiology 1994;193:239245.

    • Search Google Scholar
    • Export Citation
  • 25

    Grossman HB, Natale RB, Tangen CM et al. . Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859866.

    • Search Google Scholar
    • Export Citation
  • 26

    Sherif A, Holmberg L, Rintala E et al. . Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol 2004;45:297303.

    • Search Google Scholar
    • Export Citation
  • 27

    Winquist E, Kirchner TS, Segal R et al. . Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 2004;171:561569.

    • Search Google Scholar
    • Export Citation
  • 28

    Juffs HG, Moore MJ, Tannock IF. The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. Lancet Oncol 2002;3:738747.

    • Search Google Scholar
    • Export Citation
  • 29

    Lehmann J, Retz M, Wiemers C et al. . Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol 2005;23:49634974.

    • Search Google Scholar
    • Export Citation
  • 30

    Stöckle M, Meyenburg W, Wellek S et al. . Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 1992;148:302307.

    • Search Google Scholar
    • Export Citation
  • 31

    Lehmann J, Franzaring L, Thüroff J et al. . Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer. BJU Int 2006;97:4247.

    • Search Google Scholar
    • Export Citation
  • 32

    Loehrer PJ Sr, Einhorn LH, Elson PJ et al. . A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10:10661073.

    • Search Google Scholar
    • Export Citation
  • 33

    Lorusso V, Manzione L, de Vita F et al. . Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial. J Urol 2000;164:5356.

    • Search Google Scholar
    • Export Citation
  • 34

    Roberts JT, von der Maase H, Sengeløv L et al. . Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann Oncol 2006;17 (Suppl 5):v118122.

    • Search Google Scholar
    • Export Citation
  • 35

    Scher HI. Chemotherapy for invasive bladder cancer: neoadjuvant versus adjuvant. Semin Oncol 1990;17:555565.

  • 36

    Kata EJ, Herr H. The role of transurethral resection for muscle invasive bladder carcinoma [abstract]. J Urol 1993;149:Abstract 316A.

  • 37

    Sweeney P, Kursh ED, Resnick MI. Partial cystectomy. Urol Clin North Am 1992;19:701711.

  • 38

    Shipley WU, Winter KA, Kaufman DS et al. . Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of RTOG 89-03. J Clin Oncol 1998;16:35763583.

    • Search Google Scholar
    • Export Citation
  • 39

    Shipley WU, Kaufman DS, Zehr E et al. . Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002;60:6267.

    • Search Google Scholar
    • Export Citation
  • 40

    Russell KJ, Boileau MA, Higano C et al. . Combined 5-fluorouracil and irradiation for transitional cell carcinoma of the urinary bladder. Int J Radiat Oncol Biol Phys 1990;19:693699.

    • Search Google Scholar
    • Export Citation
  • 41

    Russell KJ, Boileau MA, Ireton RC et al. . Transitional cell carcinoma of the urinary bladder: histologic clearance with combined 5-FU chemotherapy and radiation therapy. Preliminary results of a bladder-preservation study. Radiology 1988;167:845848.

    • Search Google Scholar
    • Export Citation
  • 42

    Housset M, Maulard C, Chretien Y et al. . Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993;11: 21502157.

    • Search Google Scholar
    • Export Citation
  • 43

    Orsatti M, Curotto A, Canobbio L et al. . Alternating chemo-radiotherapy in bladder cancer: a conservative approach. Int J Radiat Oncol Biol Phys 1995;33:173178.

    • Search Google Scholar
    • Export Citation
  • 44

    Zietman AL, Shipley WU, Kaufman DS et al. . A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer. J Urol 1998;160:16731677.

    • Search Google Scholar
    • Export Citation
  • 45

    Kauffman D, Raghavan D, Carducci M et al. . Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000;18:19211927.

    • Search Google Scholar
    • Export Citation
  • 46

    Sternberg CN, de Mulder PH, Schornagel JH et al. . Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer protocol No. 30924. J Clin Oncol 2001;19:26382646.

    • Search Google Scholar
    • Export Citation
  • 47

    Von der Maase H, Hansen SW, Roberts JT et al. . Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:30683077.

    • Search Google Scholar
    • Export Citation
  • 48

    Lorusso V, Manzione L, de Vita F et al. . Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial. J Urol 2000;164:5356.

    • Search Google Scholar
    • Export Citation
  • 49

    Meluch AA, Greco FA, Burris HA III et al. . Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol 2001;19:30183024.

    • Search Google Scholar
    • Export Citation
  • 50

    Dreicer R, Manola J, Schneider DJ et al. . Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. Cancer 2003;97:27432747.

    • Search Google Scholar
    • Export Citation
  • 51

    Bellmunt J, Guillem V, Paz-Ares L et al. . Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol 2000;18:32473255.

    • Search Google Scholar
    • Export Citation
  • 52

    Hussain M, Vaishampayan U, Du W et al. . Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001;19:25272533.

    • Search Google Scholar
    • Export Citation
  • 53

    Sweeney CJ, Roth BJ, Kabbinavar FF et al. . Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 2006;24:34513457.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 378 91 11
PDF Downloads 253 108 18
EPUB Downloads 0 0 0